Hythiam, Inc. provides through its Catasys® subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys Substance Dependence Program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary Prometa® Treatment Program for alcoholism and stimulant dependence. The Prometa Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers.

> Hythiam Leadership Team
> Board of Directors

Only a physician licensed to treat with the Prometa Treatment Program can determine if it is appropriate for any individual patient. The medications used in the Prometa Treatment Program are Food and Drug Administration (FDA) approved for uses other than treating dependence on alcohol, cocaine or methamphetamine. Therefore, the risks and benefits of using these medications to treat dependence on these substances have not been evaluated by the FDA.

Hythiam does not manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the Prometa Treatment Program.